An Antibody to Notch2 Reverses the Osteopenic Phenotype of Hajdu-Cheney Mutant Male Mice.
Notch receptors play a central role in skeletal development and bone remodeling. Hajdu-Cheney syndrome (HCS), a disease characterized by osteoporosis and fractures, is associated with gain-of-NOTCH2 function mutations. To study HCS, we created a mouse model harboring a point 6955C>T mutation in the Notch2 locus upstream of the proline, glutamic acid, serine, and threonine domain, leading to a Q2319X change at the amino acid level. Notch2Q2319X heterozygous mutants exhibited cancellous and cortical bone osteopenia. Microcomputed tomography demonstrated that the cancellous and cortical osteopenic phenotype was reversed by the administration of antibodies generated against the negative regulatory region (NRR) of Notch2, previously shown to neutralize Notch2 activity. Bone histomorphometry revealed that anti-Notch2 NRR antibodies decreased the osteoclast number and eroded surface in cancellous bone of Notch2Q2319X mice. An increase in osteoclasts on the endocortical surface of Notch2Q2319X mice was not observed in the presence of anti-Notch2 NRR antibodies. The anti-Notch2 NRR antibody decreased the induction of Notch target genes and Tnfsf11 messenger RNA levels in bone extracts and osteoblasts from Notch2Q2319X mice. In vitro experiments demonstrated increased osteoclastogenesis in Notch2Q2319X mutants in response to macrophage colony-stimulating factor and receptor activator of nuclear factor-κB ligand, and these effects were suppressed by the anti-Notch2 NRR. In conclusion, Notch2Q2319X mice exhibit cancellous and cortical bone osteopenia that can be corrected by the administration of anti-Notch2 NRR antibodies.
Departments of Orthopaedic Surgery, UConn Musculoskeletal Institute, UConn Health, Farmington, CT, USA.|Department of Medicine, UConn Musculoskeletal Institute, UConn Health, Farmington, CT, USA.|The UConn Musculoskeletal Institute, UConn Health, Farmington, Connecticut, USA.
Ernesto
E
Canalis
Departments of Orthopaedic Surgery, UConn Musculoskeletal Institute, UConn Health, Farmington, CT, USA.|The UConn Musculoskeletal Institute, UConn Health, Farmington, Connecticut, USA.
Archana
A
Sanjay
Departments of Orthopaedic Surgery, UConn Musculoskeletal Institute, UConn Health, Farmington, CT, USA.|The UConn Musculoskeletal Institute, UConn Health, Farmington, Connecticut, USA.
Jungeun
J
Yu
Departments of Orthopaedic Surgery, UConn Musculoskeletal Institute, UConn Health, Farmington, CT, USA.|Department of Medicine, UConn Musculoskeletal Institute, UConn Health, Farmington, CT, USA.|The UConn Musculoskeletal Institute, UConn Health, Farmington, Connecticut, USA.
Stefano
S
Zanotti
D000818:Animals; D000906:Antibodies / Q000494:pharmacology / Q000627:therapeutic use*; D001851:Bone Diseases, Metabolic / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology; D016723:Bone Remodeling / Q000187:drug effects* / Q000276:immunology; D000071556:Cancellous Bone / Q000000981:diagnostic imaging* / Q000187:drug effects / Q000276:immunology; D004195:Disease Models, Animal; D005269:Femur / Q000000981:diagnostic imaging / Q000187:drug effects / Q000276:immunology; D031845:Hajdu-Cheney Syndrome / Q000188:drug therapy* / Q000235:genetics / Q000276:immunology; D008297:Male; D051379:Mice; D051883:Receptor, Notch2 / Q000276:immunology*; D016896:Treatment Outcome; D055114:X-Ray Microtomography
D000906:Antibodies; D051883:Receptor, Notch2